Company news

Senseonics Holdings, Inc. (NASDAQ:SENS) news

Senseonics Holdings, Inc. news releases on 6ix. Latest, Sep 16, 2026: Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC…

Senseonics Holdings, Inc. (NASDAQ:SENS) news

Press releases & updates

Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public Offering

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense(R) 365 with the iLet(R) Bionic Pancreas

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Senseonics To Participate in Upcoming Institutional Investor Conferences

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time

Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

SENS short-form announcement: year-end results (Short form report year end results)

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time

Senseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded Warrants

Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants

Senseonics Announces European Launch of Eversense 365, The World's First and Only One Year CGM System

Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

Senseonics Announces Transfer to Nasdaq Stock Exchange

Senseonics Holdings, Inc. Reports Third Quarter Financial Results

Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time

Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update

Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

Senseonics Holdings, Inc. Reports Second Quarter Financial Results

Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement

Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement

Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time

Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch

Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results

Senseonics Holdings, Inc. Announces $16 Million Registered Direct Offering

Senseonics Holdings, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for November 7, 2024 at 4:30 P.M. Eastern Time

Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System

Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor

Eversense 365 Launches in the US: One Year. One CGM.

Eversense 365 Receives FDA Clearance: The World’s First One Year CGM